RESUMEN
BACKGROUND: Neonatal seizures are often refractory to treatment with initial antiseizure medications. Clinicians turn to agents such as levetiracetam despite the paucity of published data regarding its safety, tolerability, or efficacy in the neonatal population. PATIENT PRESENTATION: We describe a neonate who developed anaphylactic shock developing after receiving intravenous levetiracetam. RESULTS: This is the first neonate to develop anaphylactic shock due to intravenous administration of levetiracetam. CONCLUSION: Clinicians should be aware of this potentially fatal adverse effect occurring with intravenous levetiracetam in newborns.
Asunto(s)
Anafilaxia/inducido químicamente , Anticonvulsivantes , Erupciones por Medicamentos/etiología , Piracetam/análogos & derivados , Anafilaxia/metabolismo , Anafilaxia/terapia , Anticonvulsivantes/uso terapéutico , Asfixia Neonatal/complicaciones , Contraindicaciones , Exantema/inducido químicamente , Exantema/metabolismo , Cara/patología , Sufrimiento Fetal , Humanos , Recién Nacido , Infusiones Intravenosas , Pierna/patología , Levetiracetam , Piracetam/uso terapéutico , Neumotórax/complicaciones , Cuero Cabelludo/patología , Convulsiones/complicaciones , Convulsiones/tratamiento farmacológicoRESUMEN
Newborn infants are born with an immature innate immunity. They are less likely to develop anaphylaxis since their immune system is weaker than older infants and children. There are only a few reports of side effects after vitamin K injection in neonates although prophylaxis against hemorrhagic disease of the newborn with this drug has been in routine practice in all over the world for many years. We herein report a case of anaphylactic shock developing after the intramuscular administration of vitamin K1 in a newborn. To our knowledge, this patient is the first case of neonatal anaphylactic shock developing due to intramuscular administration of vitamin K1. We suggest the clinicians should be aware of this possibility of potentially fatal adverse effect occurring with intramuscular administration of vitamin K1.
Asunto(s)
Anafilaxia/inducido químicamente , Enfermedades del Recién Nacido/inducido químicamente , Vitamina K/efectos adversos , Anafilaxia/congénito , Hemorragia Cerebral/congénito , Hemorragia Cerebral/prevención & control , Femenino , Humanos , Recién Nacido , Inyecciones Intramusculares , Masculino , Embarazo , Vitamina K/administración & dosificación , Adulto JovenRESUMEN
There are only a few reports on side effects after heel prick in neonates although heel prick has been performed all over the world for many years. The medicine staff had obtained only a drop of blood by pricking the baby's heel using a lancet without compressing the heel or foot to measure his blood glucose level 3 hours after birth. However he developed a severe and hemorrhagic skin reaction on his entire left foot, beginning 30 minutes after obtaining the drop of blood by pricking the baby's heel using a lancet. The lesion, which was treated with topical mupirocin and povidone-iodine solution daily, slowly decreased in size and had almost fully resolved within 3 weeks. He was healthy and 9 months old at the time of writing this paper. We herein report a case of foot skin ischemic necrosis following heel prick in a newborn. To our knowledge this patient is the first case of foot skin ischemic necrosis due to heel prick in newborns.
